Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2021-09-19 AGM Information
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Revised Date of AGM 1 page 440.1KB
AGM Information Classification · 95% confidence The document is a short announcement from Regeneus Ltd regarding a change in the date of its Annual General Meeting (AGM) and the revised closing date for director nominations. It references the AGM date change and nomination deadline but does not contain the AGM materials or the full report. The document is only 1322 characters long and states that details and a formal notice of the AGM will be made available later. This fits the pattern of an announcement about AGM logistics rather than the AGM materials themselves. Therefore, it should be classified as AGM Information (AGM-R).
2021-09-19 English
Appendix 4E - Preliminary final report-unaudited 11 pages 1.0MB
Annual Report Classification · 95% confidence The document is titled 'REGENEUS LTD (ASX:RGS) RESULTS FOR THE YEAR ENDED 30 JUNE 2021' and includes an Appendix 4E Preliminary final report - unaudited for the year ended 30 June 2021. It contains detailed financial statements such as the Consolidated Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, and Cash Flows. The document also includes a review of operations, commentary on results, additional information, and notes on accounting standards and contingencies. The report is unaudited but is a comprehensive financial report for the full fiscal year ending 30 June 2021. The presence of full financial statements and detailed analysis indicates this is a full annual financial report rather than a brief announcement or a certification. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are typically annual reports or preliminary annual financial statements. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2021
2021-08-30 English
Date of AGM 1 page 441.6KB
AGM Information Classification · 95% confidence The document is a short announcement from Regeneus Ltd regarding the date of its upcoming Annual General Meeting (AGM) and the closing date for director nominations. It references the AGM date and procedural details but does not contain the AGM materials or presentations themselves. The document is only 1205 characters long, indicating it is a brief notice rather than a full report. It states that details and a formal notice of the AGM will be made available later, implying this is a preliminary announcement. According to the classification rules, such a short announcement about the AGM date and nominations is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM itself. It is not an Annual Report or Proxy Solicitation, nor is it a Regulatory Filing since it specifically relates to the AGM date and nominations. Therefore, the correct classification is AGM-R with high confidence.
2021-08-18 English
Lapse of Unlisted Share Options 1 page 131.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9 August 2021 regarding the lapse of unlisted share options due to the resignation of a company officer. It lists the number of lapsed options and remaining options with exercise prices and expiry dates. There is no financial report, earnings data, or detailed analysis. The document is short (1811 characters) and serves as a notification about share options lapsing, which is related to capital structure but specifically about share options lapsing due to resignation. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's capital instruments (share options). It is not a full financial report, earnings release, or regulatory filing. Therefore, the classification is CAP with high confidence.
2021-08-08 English
Notification of cessation of securities - RGS 4 pages 24.2KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of certain securities (options) for the entity REGENEUS LTD. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There is no financial report, earnings data, or management discussion. The document is an official announcement related to changes in the company's securities, specifically cessation of securities, which fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like share issues or capital changes (SHA) or director dealings (DIRS). The document is relatively short and focused on a specific regulatory notification.
2021-08-08 English
Lapse of Unlisted Share Options - correction 1 page
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 9 August 2021 regarding the lapse of unlisted share options and correction of the total number of options remaining on issue. It provides specific details about the number of options, exercise prices, and expiry dates. The content focuses on share options and their status, which relates to capital structure changes. The document is short (1578 characters) and is an announcement rather than a detailed report or financial statement. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as option lapses.
2021-08-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.